Articles tagged with Radiation Therapy
A randomized trial found that high-dose radiation therapy reduced the risk of prostate cancer recurrence by 49% compared to conventional-dose therapy. The study showed improved biochemical control and local tumor control without significant differences in overall survival rates or adverse effects.
Researchers found direct decompressive surgery plus postoperative radiotherapy to be the most effective treatment, enabling 84% of patients to walk after treatment. This approach also reduced dependence on corticosteroids and opiod analgesics, showing significant benefits for patients with metastatic cancer.
A large study found that young children with medulloblastoma are at risk of impaired reading skills after radiation therapy, even if they receive lower doses. The greatest decline in IQ and reading skills occurred in patients younger than 7 years old.
Researchers found that HIF-1 inhibition impacts tumor biology differently depending on the local environment, with proximal cells less affected. This study suggests optimizing HIF-1 blockade to maximize effects on vasculature and minimize effects on distal tumor cells.
Researchers found that immediate postoperative radiotherapy significantly improved biochemical progression-free survival for patients at risk of relapse, with a 74% success rate compared to 53%. Long-term follow-up is needed to assess its effects on distant metastases and survival.
A recent study published in The Lancet found that a single dose of chemotherapy is comparable to radiotherapy in treating stage 1 seminoma. Patients who received chemotherapy had fewer seminomas occurring in their remaining testicle and were less likely to develop tumors.
A study of 60 male and 4,181 female breast cancer patients found that men were almost six times more likely to receive radiotherapy than women with similar disease stages. The researchers concluded that men should be treated using the same guidelines as women for radiotherapy treatment.
A study of 1500 men with locally confined prostate cancer found that delaying radiation therapy did not affect overall survival, disease-specific survival, or treatment failure rates. This research provides reassurance for patients considering delayed treatment, allowing them to make informed decisions.
A daily bioadhesive buccal tablet containing 50mg of miconazole has been shown to be as effective as a four-times-daily mouth gel in treating oropharyngeal candidiasis among head and neck cancer patients. This simpler treatment schedule may improve quality of life and increase patient compliance.
Researchers have developed a new treatment called RADPLAT, which combines radiation and cisplatin delivered directly to the tumor via tiny catheters. This approach has shown encouraging results in patients with advanced stage IV-T4 disease, with high rates of local and regional tumor control and overall survival.
Researchers found that tamoxifen significantly reduced the frequency of breast enlargement and breast pain compared to radiotherapy. The study showed that tamoxifen is a more effective treatment for preventing these side effects in prostate cancer patients.
A study found that women with left-sided breast cancer had a higher risk of death from ischemic heart disease after radiation therapy, but this increased risk declined over time. Advances in radiation techniques have reduced the dose to the heart, resulting in lower mortality rates among women diagnosed with right-sided breast cancer.
A meta-analysis of nine randomized trials found no significant difference in death rates or disease progression between neoadjuvant and adjuvant systemic therapy. However, neoadjuvant therapy was associated with a higher risk of loco-regional disease recurrence when radiation therapy was used without surgery.
The addition of locoregional radiation therapy significantly improved breast cancer survival and reduced mortality in high-risk patients. A 20-year follow-up study found that the regimen resulted in a 32% reduction in breast cancer mortality and a 27% reduction in overall mortality compared to chemotherapy alone.
Researchers found that PGE2 activates AKT phosphorylation events to block bax translocation and prevent cell death in radiation-exposed mice. This mechanism suggests that PGE2 or similar drugs could reduce radiation-induced small intestine injury, but may not be effective for cancers with mutated bax.
A study of 189 breast cancer patients found no association between paclitaxel chemotherapy and radiation pneumonitis. No hospitalized cases or deaths from the side effect occurred, regardless of treatment group.
The U.Va. Health System's new TomoTherapy system provides precise radiation therapy with 3-D imaging, reducing high-dose exposure to healthy tissue and potential side effects for cancer patients. The technology also enables faster treatment times and improved accuracy in targeting tumors.
Combination therapy of radiotherapy and cetuximab significantly improves loco-regional control, median survival, and overall survival rates in patients with loco-regionally advanced squamous cell carcinoma of the oropharynx, hypopharynx, or larynx. The treatment also showed minimal enhancement of toxicity compared to radiotherapy alone.
A new radiotherapy regime has been shown to significantly reduce local disease recurrence rates in young women with breast cancer. The treatment involves adding a boost dose of radiation to the tumour bed, resulting in a 5-year local recurrence rate of 8.5% in women under 35 years old.
Increased investment in radiotherapy can significantly improve cure rates for European cancer patients. In the UK and Netherlands, calls for increased funding led to substantial improvements. However, under- utilization of radiotherapy is common in many EU countries due to inadequate infrastructure and staffing.
The GENEPI project aims to predict radiotherapy efficacy and side effects based on genetic, physical, and patient-related factors. It will establish a pan-European database on radiation-related morbidity, enabling researchers to investigate factors influencing individual responses to radiotherapy.
A randomised clinical trial found that post-operative radiotherapy significantly improved biological and clinical progression-free survival in men with high-risk prostate cancer. The study showed a clear benefit in terms of biological progression-free survival for men who received radiotherapy treatment in addition to surgery.
African-American men reported significantly higher sexual and urinary function five years after prostatectomy compared to non-Latino white men. However, they also experienced slightly more bother from changes in their function.
A study by Mitchell Machtay found that correcting anemia does not improve tumor control or survival in head and neck cancer patients. Despite increasing red blood cell count, erythropoietin did not enhance radiation therapy outcomes.
Intensity modulated radiation therapy (IMRT) significantly reduces radiation dose to healthy breast tissue, limiting side effects and improving treatment outcomes. By administering precise doses of radiation at the tumor site, IMRT can spare patients from skin irritation, breakdown, and scarring of the lungs.
A study by Fox Chase Cancer Center found that prostate cancer patients with intermediate-risk disease do not require long-term androgen deprivation if they receive high-dose radiation above 76 Gy. High doses of radiation were associated with better outcomes in this patient group.
Researchers at Mount Sinai present groundbreaking studies on prostate and breast cancer treatments, identifying genetic predictors for adverse side effects and developing tailored radiotherapy regimens. The studies aim to improve clinical trials and patient outcomes for these devastating diseases.
A new study found that prostate cancer treatment can significantly impact men's quality of life, with both radical prostatectomy and radiotherapy causing declines in sexual function, urinary incontinence, and bowel issues. The study, which followed over 1,100 men with clinically localized prostate cancer, suggests that the treatments d...
A study of over 600 older women with receptor-positive breast tumors found that tamoxifen alone was as effective as radiation therapy in preventing recurrence. The research suggests that radiation may not be necessary for these patients, improving their quality of life and reducing side effects.
A randomized clinical trial found that combining six months of hormone therapy with radiation therapy reduced the risk of death from prostate cancer by two-fold. Patients treated with this combination therapy had a lower risk of requiring salvage hormone therapy in the long term.
Using combination therapies that include 6 months of androgen suppression therapy (AST) alongside radiation therapy (RT) improves survival rates for patients with locally advanced prostate cancer. The study found significantly higher survival rates, lower prostate cancer-specific mortality, and a reduced need for salvage AST in the com...
A new study by Mount Sinai School of Medicine researchers found that combining three therapeutic modalities increases the percentage of high-risk patients who are free from recurrence after five years. A three-pronged approach that included brachytherapy, external beam radiation therapy and hormonal therapy produced an 86 percent rate ...
Accelerated partial breast irradiation (APBI), also known as brachytherapy, treats breast cancer with minimal radiation exposure. This technique reduces treatment time to four to five days and improves convenience for women with busy lifestyles or rural locations.
A study using FMISO-PET scans found that high uptake of the tracer correlates with a greater risk of tumor recurrence, while low uptake is associated with a longer survival rate. The technique may enable more precise prediction of therapeutic outcomes and improved patient treatment.
Researchers at Duke University Medical Center have identified a protein called Hypoxia Inducible Factor (HIF-1) as the master switch that enables blood vessels to survive and nourish remaining cancer cells after radiation therapy. By suppressing HIF-1 with experimental drugs, they successfully inhibited tumor growth in animals.
A new standard of care has been established for treating brain metastases, offering improved prognosis and quality of life for patients. Combining radiation therapy with different modalities shows significant benefits in managing this type of cancer.
New research reveals that hypoxia-inducible factor-1 (HIF-1) plays a key role in tumor cells' ability to resist radiation therapy. By understanding how this protective response is activated, scientists hope to develop effective treatments to enhance radiation's effectiveness against tumors.
A recent study has confirmed that women with BRCA breast cancer who undergo conservation surgery and radiotherapy have a lower risk of recurrence compared to those without genetic mutations. The only factor associated with a higher risk of recurrence is young age, according to the researchers.
Researchers found a 1.7-fold increase in cardiovascular death among breast cancer patients who received radiotherapy compared to those who didn't. However, the risk was lower for non-irradiated patients, suggesting that breast cancer may have a protective effect on cardiovascular disease.
A study of 501 patients with recurrent prostate cancer found that salvage radiotherapy can be effective for patients with high-grade disease and rapid PSA doubling time, suggesting it may prevent metastatic disease progression. The study's findings support early treatment for these patients, who are at the highest risk of disease spread.
The study found that 97.5% of patients with DCIS underwent surgery, but there is a wide variation in treatment approaches, including the use of mastectomy, radiation therapy, and axillary dissection. The incidence of DCIS increased by 73% between 1992 and 1999, highlighting the need for standardized treatment recommendations.
Proton radiotherapy is being used to treat cancer patients at MPRI with minimal damage to healthy cells. The facility has received $10 million in funding and will be a centerpiece of the life sciences effort in Indiana.
A pooled analysis of 15 clinical trials reveals that radiotherapy significantly reduces breast cancer recurrence and mortality rates after breast-conserving surgery. Women who received radiotherapy had a lower risk of relapse and mortality compared to those who underwent surgery alone.
A study of 33 elderly men with advanced prostate cancer found that external beam radiation therapy was well-tolerated and effective in keeping the cancer at bay. The patients experienced no unusual interruptions in treatment due to illness from radiation, and many remained alive and disease-free for several years.
A study published in Cancer Research found that combining gene therapy and radiation therapy showed significant declines in PSA levels and eliminated cancer in many patients. The novel treatment has shown promise in treating aggressive prostate cancer, but more research is needed before it can be widely adopted.
A study of 85 breast cancer patients reveals low complication rates for reconstruction after radiation therapy, with no major complications in TRAM flap recipients and only 5% of implant patients experiencing major complications. The study also found that TRAM patients had superior cosmetic scores compared to implant recipients.
A study by Pollack and colleagues finds that a high Ki-67 biomarker is linked to increased risk of distant metastasis and death in prostate cancer patients. The researchers also suggest that Ki-67 can help identify high-risk patients who may benefit from alternative treatment strategies.
A 10-year study found high doses of radiation improved outcomes for patients with localized prostate cancer, regardless of risk group. Minimal side effects were observed despite higher radiation doses.
A study tested the ASTRO consensus definition of biochemical failure after combined radiation treatment and hormone therapy, finding it may not accurately predict future disease progression. The study suggests that approximately 20-30% of patients will experience biochemical failure but not continued rises in PSA levels
High doses of radiation therapy directed at the prostate significantly impact cancer control in high-risk patients. The major site of treatment failure is the prostate, highlighting the importance of high doses in this group.
A multicentre trial involving 351 patients found that anaemia treatment with epoetin beta did not improve cancer control or survival rates. Instead, patients receiving epoetin beta had a 60% better chance of progression-free survival compared to those given placebo.
Researchers identified specific genetic variations linked to differences in normal tissue radiation damage, potentially allowing for personalized treatment approaches. The study's findings suggest that a person's genetic pattern can predict their tolerance to radiotherapy, enabling more effective treatment and reduced side effects.
A randomised controlled trial found that accelerated radiotherapy improved five-year tumour control by 10% compared to standard radiotherapy, with benefits also seen in patients with laryngeal cancer. The treatment was associated with a small increase in disease-specific survival, but also more acute morbidity.
A new trial has shown that faster radiotherapy can improve head and neck cancer treatment outcomes, with a 60-70% benefit in tumour control and better voice conservation. The study found that accelerated treatment was linked to high EGFR expression and good tumour differentiation.
A study examined whether limited-field radiation therapy could be an effective alternative to whole-breast radiation therapy for patients at low risk of recurrence. The results showed no significant difference in local recurrence rates or overall survival between the two groups after five years of follow-up.
A study of 1700 women found that radiotherapy significantly reduced the risk of recurrent ductal carcinoma in situ (DCIS) in the same breast by over 60%. However, tamoxifen had no effect on reducing invasive cancer risk. The results suggest that radiotherapy may be beneficial for younger patients with DCIS detected by mammography.
A new study found that chemotherapy and radiotherapy together reduce surgery and removal of the voice box due to cancer recurrence. The combination treatment was associated with a significantly lower rate of surgeries compared to standard therapy or radiotherapy alone.
A new radiotherapy strategy, hyperfractionated accelerated radiotherapy (HART), has been shown to improve survival rates for lung cancer patients. In a phase III multi-site study, chemotherapy followed by HART resulted in a median survival of 21 months, compared to 12 months with standard radiation therapy.
Researchers genetically inactivated an enzyme, acid sphingomyelinase, to show that damage to endothelial cells is another way radiation kills tumor cells. Tumors without the enzyme were radioresistant, while those with it responded well to low doses of radiation.
Researchers found no difference in life expectancy between single- and multiple-fraction radiotherapy for painful bone metastases. Single-fraction radiotherapy is more cost-effective, with a lower treatment cost of $2,438 compared to $3,311 for multiple-fraction radiotherapy.